Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

2.

EBCC: European Breast Cancer Conference

3.

Germline Variants Predict Lobular Breast Cancer Recurrence

4.

A Win for Molecularly Guided Therapy for Cancer of Unknown Primary

5.

Joe Biden has prostate cancer with bone spread. An oncologist explains what you need to know


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot